Role of radionuclide imaging in trials of antiangiogenic therapy

Academic Radiology

Volumn 7, Issue 10, 2000, Pages 851-867

  Blankenberg, Francis ^a   Eckelman, William ^b   Strauss, H William ^c   Welch, Michael ^d   Alavi, Abass ^e   Anderson, Carolyn ^d   Bacharach, Stephen ^b   Blasberg, Ronald ^f   Graham, Michael ^g   Weber, Wolfgang ^h  

^a LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c STANFORD UNIVERSITY   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g UNIVERSITY OF IOWA   (United States)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; ALBUMIN I 131; ALBUMIN TC 99M; ANGIOGENESIS INHIBITOR; ANNEXIN V TC 99M; APOMATE; BRU 59 21; COPPER 60; COPPER 61; COPPER 62; COPPER 64; COPPER DIACETYL BIS(N 4 METHYLTHIOSEMICARBAZONE); ERYTHROCYTE TC 99M; FLUORODEOXYTHYMIDINE F 18; GA 67 TRANSFERRIN; GALLIUM 68; IODINE 123; IODINE 125; IODOQUINUCLIDINYL BENZYLATE I 123; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; NITROIMIDAZOLE DERIVATIVE; OXO[3,3,9,9 TETRAMETHYL 1 (2 NITRO 1H IMIDAZOL 1 YL) 4,8 DIAZAUNDECANE 2,10 DIONEDIOXIMATO]TECHNETIUM TC 99M; OXYGEN 15; PROMEGESTONE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; THALLIUM 201; UNCLASSIFIED DRUG; UNINDEXED DRUG; UPENAZIME; UPENAZIME TC 99M; XENON 133;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BINDING SITE; CANCER THERAPY; CELL PROLIFERATION; CLINICAL TRIAL; DRUG DESIGN; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG UPTAKE; GENE EXPRESSION; HUMAN; HYPOXIA; METABOLISM; MONITORING; NONHUMAN; NUCLEAR MEDICINE; OPTICAL RESOLUTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOISOTOPE DECAY; RECEPTOR BINDING; RECEPTOR DENSITY; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR BLOOD FLOW;

EID: 0033779219     PISSN: 10766332     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1076-6332(00)80633-9     Document Type: Article

References (156)

1. The design of site directed radiopharma-ceuticals for use in drug discovery
2. Receptor-binding radiotracers: A class of potential radiopharmaceuticals
3. Sensitivity of new radiopharmaceuticals
4. Tumor angiogenesis
5. Mechanisms of angiogenesis
6. Clinical applications of research on angiogenesis
7. Tumoural vascularity as a prognostic factor in cancer patients: The evidence continues to grow
8. The prognostic value of tumor blood vessel morphology in primary uveal melanoma
9. Integrins and vascular extracellular matrix assembly
10. Requirement of vascular integrin alpha v beta 3 for angiogenesis
11. Requirement of the integrin beta 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen
12. Integrin beta 1- and beta 3-mediated endothelial cell migration is triggered through distinct signaling mechanisms
13. Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen
14. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
15. Vascular channel formation by human melanoma celts in vivo and in vitro: Vasculogenic mimicry
16. Quo vadis radioimmune imaging
17. Isolation of angiopoietin-1, a ligand for the TE2 receptor, by secretion-trap expression cloning
18. Tumor angiogenesis: Therapeutic implications
19. Hypoxia-inducible factor 1 and the molecular physiology of oxygen homeostasis
20. Hypoxic induction of endothelial cell growth factors in retinal cells: Identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen
21. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate
22. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: Validation of method
23. Graphical evaluation of blood-to-brain transfer constants from multiple- time uptake data
24. SUV: Standard uptake or silly useless value?
25. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: Theory, procedure, and normal values in the conscious and anesthetized albino rat
26. Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG: Analysis of the FDG lumped constant
27. Glycolysis-induced discordance between glucose metabolic rates measured with radiolabeled fluorodeoxy-glucose and glucose
28. 99Tcm-MIBI scintimammography in the evaluation of breast lesions and axillary involvement: A comparison with mammography and histopathological diagnosis
29. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography
30. Evaluating benign and malignant bone and soft-tissue lesions with technetium-99m-MIBI scintigraphy
31. Prediction of the chemosensitivity of lung cancer by 99mTc-hexakis-2- methoxyisobutyl isonitrile SPECT
32. Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: A rapid and noninvasive dynamic method
33. Relationship of perfusion to edema in the 9L gliosarcoma
34. Blood flow rate in normal and tumor-bearing rats in conscious state, under urethane anesthesia, and during systemic hypothermia
35. Changes of cerebral blood flow, and oxygen and glucose metabolism following radiochemo-therapy of gliomas: A PET study
36. Brain oxygen utilization measured with O-15 radiotracers and positron emission tomography
37. Oxygen consumption of the living human brain measured after a single inhalation of positron emitting oxygen
38. A simple, dual tracer method for the measurement of transvascular flux of albumin into the lung
39. Evaluating pulmonary vascular permeability with radiolabeled proteins: An error analysis
40. Effect of bicarbonate on stability of the gallium-transferrin complex
41. Noninvasive detection of hypoxic myocardium using fluorine-18-fluoromisonidazole and positron emission tomography
42. An efficient radiosynthesis of [18F] fluoromisonidazole
43. Hypoxic cervical cancers with low apoptotic index are highly aggressive
44. Oncogenic alterations of metabolism
45. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: Effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts
46. Angiogenesis
47. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only
48. A radio-synthesis of fluorine-18 fluoromisonidazote
49. Myocardial kinetics of fluorine-18 misonidazole: A marker of hypoxic myocardium
50. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole
51. A modeling approach for quantifying tumor hypoxia with [F-18]fluoromisonidazole PET time-activity data
52. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography
53. Synthesis and characterization of lipophilic 1-[18F]fluoroalkyl-2- nitroimidazoles for imaging hypoxia
54. Non-invasive assessment of human tumour hypoxia with 1231-iodoazomycin arabinoside: Preliminary report of a clinical study
55. In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia
56. Technetium-99m-labeled HL91 to identify tumor hypoxia: Correlation with fluorine-18-FDG
57. BRU59-21, a second-generation 99mTc-labeled 2-nitroimidazole for imaging hypoxia in tumors
58. Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential
59. A potential copper radiopharmaceutical for imaging the head and brain: Copper-labeled pyruvaldehyde bis(N4-methylthiosemicarbazone)
60. Copper-62-labeled pyruvaldehyde bis(N4-methylthiosemicarbazonato)copper(ll): Synthesis and evaluation as a positron emission tomography tracer for cerebral and myocardial perfusion
61. Performance of a 62Zn/62Cu generator in clinical trials of PET perfusion agent 62Cu-PTSM
62. High purity production and potential applications of copper-60 and copper-61
63. Carbon-11-thymidine and FDG to measure therapy response
64. Development of a radiosynthesis for 3'-[F-18]fluoro-3'-deoxynucleosides
65. Morphological and biochemical characterization and analysis of apoptosis
66. Annexin V-affinity assay: A review on an apoptosis detection system based on phosphatidylserine exposure
67. The complexity of the phospholipid binding protein annexin V
68. Selective uptake of radio-labeled annexin V on acute porcine left atrial thrombi
69. Apoptosis in the pathogenesis and treatment of disease
70. Preparation and characterization of a disulfide-linked bioconjugate of annexin V with the B-chain of urokinase: An improved fibrinolytic agent targeted to phospholipid-containing thrombi
71. The application of receptor theory to receptor-binding and enzyme-binding oncologic radiopharmaceuticals
72. Identification of transferrin receptors on the surface of human cultured cells
73. Transferrin receptors in human cancerous tissues
74. Characterization of muscarinic cholinergic receptors in membrane preparations from rat prostatic adenocarcinoma
75. Human lung adrenergic and muscarinic cholinergic receptors in cancer and previous airways diseases
76. Fluorine-substituted corticosteroids: Synthesis and evaluation as potential receptor-based imaging agents for positron emission tomography of the brain
77. Insulin-like growth factors and cancer
78. The insulin-like growth factor II (IGF-II) gene
79. Growth factor and peptide receptors in small cell lung cancer
80. Growth stimulation of A431 cells by epidermal growth factor: Identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody
81. Partial characterization of insulin-like growth factor I in primary human lung cancers using immunohistochemical and receptor autoradiographic techniques
82. Platelet-derived growth factor: Mechanism of action and possible in vivo function
83. Somatostatin
84. Oncological applications of somatostatin analogues
85. The role of somatostatin and its analogs in the diagnosis and treatment of tumors
86. Distribution of somatostatin receptors in normal and tumor tissue
87. Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane
88. High density of somatostatin receptors in veins surrounding human cancer tissue: Role in tumor-host interaction?
89. Expression of somatostatin receptors in peritumoral veins of human tumors
90. Somatostatin receptor scintigraphy with [111ln-DTPA-D-Phe 1]- and [1231- Tyr3]octreotide: The Rotterdam experience with more than 1000 patients
91. Initial results with PET imaging using Cu-64-labeled TETA-octreotide in patients with carcinoid tumor
92. Isoquinoline and peripheral-type benzodiazepine binding in gliomas: Implications for diagnostic imaging
93. Synthesis of a high specific activity 1251-labeled analog of PK 11195, potential agent for SPECT imaging of the peripheral benzodiazepine binding site
94. Use of DES-treated rats as an animal model for assessment of pituitary adenoma imaging agents
95. In vivo measurement of dopamine receptors in pituitary adenomas using positron emission tomography
96. The role of alphav integrins during angiogenesis: Insights into potential mechanisms of action and clinical development
97. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin
98. Tumor angiogenesis: New drugs on the block
99. Alpha v integrins as receptors for tumor targeting by circulating ligands
100. Conformation/ activity studies of rationally designed potent anti-adhesive RGD peptides
101. Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins
102. Comparison of tumor uptake and biokinetics of 1251- and 18F-labeled RGD-peptides
103. Radiolabeled alpha(v)beta3 integrin antagonists: A new class of tracers for tumor targeting
104. Radioiodinated analogs and introduction of a novel glycosylated peptide with improved biokinetics
105. Structure, function and biological properties of integrin alpha v beta 3 on human melanoma cells
106. The biochemistry of cancer dissemination
107. Angiogenesis: A dynamic balance of stimulators and inhibitors
108. Metalloproteases and urokinase in angiogenesis and tumor progression
109. The pivotal role of VEGF in tumor angiogenesis: Molecular facts and therapeutic opportunities
110. Signal relays in the VEGF system
111. Tumor angiogenesis: Biology and therapeutic prospects
112. New model of tumor angiogenesis; dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF
113. Quantitative angiogenesis assays: Progress and problems
114. Hypoxia response elements
115. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src
116. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis
117. Inverse correlation between apoptotic (Fas ligand, caspase-3) and angiogenic factors (VEGF, microvessel density) in squamous cell lung carcinomas
118. Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas
119. Essential rote for oncogenic Ras in turnout maintenance
120. The turnout suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
121. Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression
122. Modulation of c-Myc activity and apoptosis in vivo
123. Hypoxia-inducible factor-1, modulates gene expression in solid tumors and influences both angiogenesis and tumor growth
124. Selection and analysis of a mutant cell line defective in the hypoxia-inducible factor-1 alpha-subunit (HIF-1alpha): Characterization of hif-1alpha-dependent and -independent hypoxia-inducible gene expression
125. A unique glucose-dependent apoptotic pathway induced by c-Myc
126. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
127. Selection of human cervical epithelial ceils that possess reduced apoptotic potential to low-oxygen conditions
128. Regulation of proliferation-survival decisions during tumor cell hypoxia
129. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
130. Tumor induction of VEGF promoter activity in stromal cells
131. Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography
132. Solution structure of the VEGF-binding domain of Flt-1: Comparison of its free and bound states
133. Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent
134. Characterization of the VEGF binding site on the Flt-1 receptor
135. KDR receptor: A key marker defining hematopoietic stem cells
136. On the mechanism of thrombin-induced angiogenesis: Potentiation of vascular endothelial growth factor activity on endothelial cells by up- regulation of its receptors
137. Two independent mechanisms essential for tumor angiogenesis: Inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway
138. Prognostic relevance of the endothelial marker CD 34 in ovarian cancer
139. Expression of von Hippel-Lindau protein in normal and pathological human tissues
140. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature
141. Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices
142. Expression of Tie2/Tek in breast turnout vasculature provides a new marker for evaluation of tumour angiogenesis
143. Transforming growth factor beta 1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma
144. Upregulation of endoglin (CD105) expression during childhood brain tumor-related angiogenesis: Anti-angiogenic therapy
145. CD44-related chondroitin sulfate proteoglycan, a cell surface receptor implicated with tumor cell invasion, mediates endothelial cell migration on fibrinogen and invasion into a fibrin matrix
146. Microvessel quantitation and prognosis in invasive breast carcinoma
147. Angiogenesis, assessed by platelet/ endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer
148. Invasive node-negative breast carcinoma: Multivariate analysis of the prognostic value of peritumoral vessel invasion compared with that of conventional clinico-pathologic features
149. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma
150. Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma
151. Imaging transgene expression with radionuclide imaging technologies
152. Regional [14C]misonidazole distribution in experimental RT-9 brain tumors
153. Imaging the expression of transfected genes in vivo
154. Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: A potential method for monitoring clinical gene therapy